ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Of interest is also a STAT3 SH2 domain-targeting compound that showed low micromolar effects (1 μM) in combination with imatinib on survival of CD34+ cells obtained from CML patients with BCR-ABL1-independent TKI resistance [60].